These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9758725)

  • 1. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.
    Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ
    J Surg Res; 1998 Oct; 79(2):115-20. PubMed ID: 9758725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.
    Tyler DS; Stanley SD; Nastala CA; Austin AA; Bartlett JA; Stine KC; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1990 May; 144(9):3375-84. PubMed ID: 2329275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients.
    Jewett A; Giorgi JV; Bonavida B
    J Immunol; 1990 Dec; 145(12):4065-71. PubMed ID: 2258607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
    Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
    Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
    Tyler DS; Nastala CL; Stanley SD; Matthews TJ; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1989 Feb; 142(4):1177-82. PubMed ID: 2536767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
    Munn DH; Cheung NK
    Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations.
    Brenner BG; Gryllis C; Gornitsky M; Cupples W; Wainberg M
    Anticancer Res; 1991; 11(2):969-74. PubMed ID: 2064353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-fungal and cytokine producing activities of CD8 + T lymphocytes from HIV-1 infected individuals.
    Colón MD; Toledo N; Valiente CL; Rodríguez N; Yano N; Mathews H; Yamamura Y
    Bol Asoc Med P R; 1998; 90(1-3):21-6. PubMed ID: 9734153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity.
    Kim JS; Nag P; Landay AL; Alves M; Cohn MH; Bremer JW; Baum LL
    FEMS Immunol Med Microbiol; 2006 Nov; 48(2):267-73. PubMed ID: 16978244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
    J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases.
    Brenner BG; Gryllis C; Wainberg MA
    J Leukoc Biol; 1991 Dec; 50(6):628-40. PubMed ID: 1940615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides.
    Cauda R; Tumbarello M; Ortona L; Kennedy RC; Shuler KR; Chanh TC; Kanda P
    Nat Immun Cell Growth Regul; 1990; 9(6):366-75. PubMed ID: 2087245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-dependent cell-mediated cytotoxicity: comparison between HTLV-I and HIV-1 assays.
    Sinclair AL; Habeshaw JA; Muir L; Chandler P; Forster S; Cruickshank K; Dalgleish AG
    AIDS; 1988 Dec; 2(6):465-72. PubMed ID: 3149493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
    Berdeja JG; Hess A; Lucas DM; O'Donnell P; Ambinder RF; Diehl LF; Carter-Brookins D; Newton S; Flinn IW
    Clin Cancer Res; 2007 Apr; 13(8):2392-9. PubMed ID: 17438098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1.
    Hildreth JE; Hampton R; Halsey NA
    Clin Immunol; 1999 Feb; 90(2):203-12. PubMed ID: 10080832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine augmentation of human immunodeficiency virus type 1 (HIV-1) gp120-specific cellular cytotoxicity.
    Stine KC; Bolognesi D; Weinhold KJ
    J Biol Response Mod; 1989 Oct; 8(5):501-10. PubMed ID: 2552026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.